CompletedNot Applicable

Combined Therapy of 532-nm KTP and Microsecond 1064-nm Nd:YAG Laser for Rosacea

China15 participantsStarted 2024-08-10

Plain-language summary

Rosacea remains a therapeutically challenging, chronic facial dermatosis whose central feature-persistent erythema-often resists topical and systemic agents. In this study we evaluated, for the first time, the simultaneous use of a 532-nm potassium titanyl phosphate (KTP) laser and a microsecond-pulsed 1064-nm Nd:YAG laser as a safe alternative.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants aged between 18 and 65 years, without cognitive impairments, and of any gender * Patients must meet the 2017 rosacea diagnostic criteria updated by the National Rosacea Society Expert Committee * The severity of rosacea must be scored at least 2 points on the Clinician's Erythema Assessment (CEA) scale. Exclusion Criteria: * if they had undergone any treatments that could influence the prognosis of rosacea within the preceding 8 weeks * if they had taken photosensitizing or phototoxic medications within the same period * the presence of other facial conditions that might confound the efficacy assessment * participation in any drug clinical trial as a subject within the last month * the presence of severe concurrent diseases

What they're measuring

CEA scores

Timeframe: Baseline to Week 9

CEA success

Timeframe: Baseline to Week 9

Trial details

NCT IDNCT07250165

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-01

View on ClinicalTrials.gov More Rosacea trials